Skip to main content

Year: 2026

MiniLuxe Announces Follow-On Investment of up to US$1.75M from Flow Capital

Company expands on its relationship with Flow Capital. Boston, MA, April 01, 2026 (GLOBE NEWSWIRE) — MiniLuxe Holding Corp. (TSXV: MNLX)(“MiniLuxe” or the “Company”), the pioneer in clean nail care and ethical nail services, is pleased to announce that Flow Capital Corporation (TSXV:FW) (“Flow Capital”), a leading provider of flexible growth capital and alternative debt solutions, has completed a follow-on investment of up to US$1.75M pursuant to its existing term loan with the Company, bringing the total amount available to the Company under the facility to up to US$7.925 million. Under the new tranche of the loan, an initial advance of US$1.35 million was funded to the Company on closing, and the Company is also eligible to receive an additional advance of up to US$400,000, subject to the satisfaction of certain financing milestones,...

Continue reading

Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease

GARDian3 trial enrollment and dosing completed (N=63) in less than nine months Topline results expected in 2Q27 with BLA to follow by mid-2027 OCU410ST represents a potential first-in-class, one-time modifier gene therapy for all ABCA4-associated retinopathiesMALVERN, Pa., April 01, 2026 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that dosing has been successfully completed ahead of schedule in the Phase 2/3 GARDian3 pivotal confirmatory clinical trial for OCU410ST (AAV5-hRORA)—a modifier gene therapy candidate developed for all Stargardt disease (ABCA4-associated retinopathies). “This enrollment milestone for a pivotal trial underscores the tremendous progress our team is making toward bringing a transformative...

Continue reading

Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity

Fast Track designation is one of the FDA’s expedited programs meant to facilitate development and expedite review of new drugs that have the potential to address an unmet medical need in the treatment of a serious or life-threatening condition MIAMI, April 01, 2026 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to PAS-004 for the treatment of NF1-associated PN causing significant morbidity. “We appreciate the FDA’s decision that PAS-004 meets the criteria for Fast Track designation for this indication,” said Dr. Tiago Reis Marques, Chief Executive Officer of Pasithea. “The ability...

Continue reading

Whitestone REIT Adds Premier Tenant at BLVD Place, Signs Agreement for Parkhill’s Houston Headquarters

Multidisciplinary architecture and engineering firm to occupy approximately 5,800 square feet at the mixed-use center HOUSTON, April 01, 2026 (GLOBE NEWSWIRE) — Whitestone REIT (NYSE: WSR), a neighborhood-focused owner and operator of open-air shopping centers in Texas and Arizona, today announced it has signed an approximately 5,800-square-foot lease with Parkhill, a multidisciplinary architecture and engineering firm, to open a new office presence in Houston at BLVD Place located in the prestigious Uptown District. The agreement highlights the type of high-credit-quality tenants that are being drawn to the mixed-use center because of its prime location and amenities. Parkhill’s second-floor workspace at BLVD Place epitomizes the type of dynamic setting that is critical for employee retention and attracting the next generation...

Continue reading

Amaze Reports Full Year 2025 Financial Results and Strategic Transformation

2025 Marked a Year of Consolidation, Platform Integration, and Strategic Foundation for Commerce-Led Growth in 2026 NEWPORT BEACH, Calif., April 01, 2026 (GLOBE NEWSWIRE) — Amaze Holdings, Inc. (NYSE American: AMZE) (“Amaze” or the “Company”), a creator-powered commerce platform enabling creators and brands to sell products globally, today reported financial results for the full year ended December 31, 2025. Management Commentary “2025 was a foundational year for Amaze,” said Aaron Day, Chief Executive Officer of Amaze. “Following the acquisition of Amaze Software and our transition from Fresh Vine into a creator-powered social commerce platform, we spent 2025 consolidating operations, strengthening our technology stack, reducing costs, and positioning the business for scalable growth.” During the year, the Company began development...

Continue reading

Man Group PLC : Form 8.3 – A consortium comprising LondonMetric Property plc and Schroder Real Estate Investment Trust Limited

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: Man Group PLC(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.  (c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree A consortium comprising LondonMetric Property plc and Schroder Real Estate Investment Trust Limited(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:  (e)   Date...

Continue reading

LVMH: AVAILABILITY OF THE 2025 UNIVERSAL REGISTRATION DOCUMENT

Paris, April 1st, 2026 LVMH Moët Hennessy Louis Vuitton announces the availability of its 2025 Universal Registration Document (URD), in accordance with applicable regulations. The French version of this document was filed with the “Autorité des marchés financiers” (AMF) on March 31st, 2026 in ESEF format (European Single Electronic Format) under the reference D.26-0195. The English translation of this document may be consulted on the Company’s website www.lvmh.com (under Investors / Investors and Analysts / Publications). It is equally available on the AMF website: www.amf-france.org. This document includes in particular: – the 2025 annual financial report;– the Board of Directors’ management report, to which are attached the Board of Directors’ report on corporate governance and the sustainability report;– the Statutory...

Continue reading

Cespira’s Hydrogen HPDI™ Fuel System Now in On-Road Testing

Advancing HPDI Technology for Hydrogen Fuel VANCOUVER, British Columbia, April 01, 2026 (GLOBE NEWSWIRE) — Westport Fuel Systems Inc. (“Westport” or the “Company”) (TSX:WPRT / Nasdaq:WPRT), a leading supplier of advanced alternative fuel systems and components for the global transportation industry, is pleased to announce that its joint venture, Cespira and their HPDI™ fuel system technology will be utilized by Volvo in on-road testing of heavy-duty trucks powered by hydrogen. Volvo has indicated that a commercial launch is planned to take place prior to 2030. “On-road testing is a key milestone in demonstrating that Cespira’s hydrogen HPDI fuel system is a cost-effective solution that operates on a zero-carbon fuel while delivering best-in-class power, torque, and efficiency,” said Dan Sceli, Chief Executive Officer...

Continue reading

Form 8.3 – [BRCK GROUP PLC – Opening Disclosure – 31 03 2026] – (CGAML)

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY ASSET MANAGEMENT LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree BRCK GROUP PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date position...

Continue reading

Cal-Maine Foods Reports Third Quarter Fiscal 2026 Results

RIDGELAND, Miss., April 01, 2026 (GLOBE NEWSWIRE) — Cal-Maine Foods, Inc. (NASDAQ: CALM) (“Cal-Maine Foods,” “we,” “us,” “our” or the “company”), the largest egg company in the United States and a leading player in the egg-based food industry, today reported results for its fiscal 2026 third quarter, ended February 28, 2026. Unless otherwise indicated, all comparisons are to the comparable period of fiscal 2025. Strategic Execution HighlightsContinued focus on sales diversification and mix shift, expected to strengthen earnings durability and predictability over time In the third quarter of fiscal 2026:Specialty eggs sales increased to 50.5% of total shell egg sales, up 2,610 basis points Prepared foods accounted for 9.5% of net sales, up 870 basis points Combined, specialty eggs and prepared foods accounted for 52.9% of net...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.